ESG Report 2025

In addition, leveraging outstanding product quality, advanced production processes and equipment, the Group continued to pursue innovation and breakthroughs and generated notable benefits. We have achieved a number of scientific research results, which not only bring more quality pharmaceutical products to the public, but also significantly enhance the Group's operating efficiency and production effectiveness. Annual Scientific Research Achievements The Group's self-developed innovative drug UBT251 Injection achieved successive breakthroughs: following approval by the National Medical Products Administration (NMPA) in January 2025 to conduct a Phase II clinical trial for chronic kidney disease, it received permission from the US FDA in February to proceed with a Phase II trial for the same indication. This product is a long-acting GLP-1/GIP/GCG triple-target receptor agonist that regulates appetite and energy metabolism, lowers blood glucose and body weight, and improves hepatic steatosis. The Group's self-developed Class 1 innovative drug UBT37034 for Injection has obtained clinical trial authorisation from both the NMPA and the US FDA for the treatment of overweight or obesity. This product is a novel peptide receptor agonist that exerts weight-reducing effects through selective action on neuropeptide Y2 receptors (Y2R). Pre-clinical studies have shown that its combination with GLP-1 analogues significantly enhances weight loss, offering a new treatment option for overweight or obese patients and further enriching the Company's innovative drug pipeline in metabolic diseases. The new drug application for the Group's Semaglutide Injection has been accepted by the NMPA, marking another important milestone for the Group in the field of diabetes treatment. As a long-acting GLP-1 analogue developed on the basis of mature technology, this product is expected to provide a new treatment option for diabetic patients and further expand the Company's product portfolio in the endocrine and metabolic therapeutic area. UBT251 Injection Approved for Clinical Trial for New Indication UBT37034 for Injection Approved for Clinical Trial New Drug Application for Semaglutide Injection Accepted Liraglutide Injection Approved for Marketing 56 ® The Group's Liraglutide Injection ( 聯邦優利泰 ) has been officially approved for marketing by the NMPA for the treatment of type 2 diabetes in adults. As the first approved product under the pilot program for segmented production of biological products in Guangdong Province, the launch of this drug not only enriches the Group's product layout targeting GLP-1 but also signifies the continuous enhancement of the Group's competitiveness in the diabetes treatment field. The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report